Home Newsfeeds Baird Downgrades Littelfuse to Neutral, Lowers Price Target to $269

Baird Downgrades Littelfuse to Neutral, Lowers Price Target to $269

Baird analyst Luke Junk downgrades Littelfuse (NASDAQ:LFUS) from Outperform to Neutral and lowers the price target from $289 to $269.

byBenzinga Newsdesk

July 6, 2022

1 minute read

Baird analyst Luke Junk downgrades Littelfuse (NASDAQ:LFUS) from Outperform to Neutral and lowers the price target from $289 to $269.

News

Mammoth Energy Announces Two Sand Supply Agreements

By Benzinga Newsdesk

November 1, 5:15 PM

Mammoth Energy Services, Inc. (NASDAQ:TUSK) ("Mammoth" or the "Company") today announced that its subsidiaries, Piranha Proppant LLC and Taylor Frac, LLC, have entered into two sand supply agreements

TUSK

Cytokinetics’ Drug Potential: Analyst Suggests Key Role Of Established Pharma For Potential Launch

By Vandana Singh

December 28, 1:19 PM

On Wednesday, Cytokinetics Incorporated (NASDAQ: CYTK) released topline results from the SEQUOIA-HCM Phase 3 trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).

BMY

Exagen Inc. And Johns Hopkins University Announce License Agreement For Novel Patented Lupus Nephritis Biomarkers

By Benzinga Newsdesk

November 9, 6:26 PM

Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, and Johns Hopkins University jointly announced today the execution of an exclusive license agreement. Exagen will focus on the

XGN